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Abstract
Background: To explore the effects of Osthole on the proliferation, cell cycle and apoptosis of human lung cancer
A549 cells.
Methods: Human lung cancer A549 cells were treated with Osthole at different concentrations. Cell proliferation
was measured using the MTT assay. Cell cycle was evaluated using DNA flow cytometry analysis. Induction of
apoptosis was determined by flow cytometry and fluorescent microscopy. The expressions of Cyclin B1, p-Cdc2,
Bcl-2, Bax, t-Akt and p-Akt were evaluated by Western blotting.
Results: Osthole inhibited the growth of human lung cancer A549 cells by inducing G2/M arrest and apoptosis.
Western blotting demonstrated that Osthole down-regulated the expressions of Cyclin B1, p-Cdc2 and Bcl-2 and
up-regulated the expressions of Bax in A549 cells. Inhibition of PI3K/Akt signaling pathway was also observed after
treating A549 cells with Osthole.
Conclusions: Our findings suggest that Osthole may have a therapeutic application in the treatment of human
lung cancer.
Background
Lung cancer is the leading cause of cancer-related death
in the world, and non-small cell lung cancer accounts for
approximately 80% of all cases [1,2]. Despite advances in
diagnostic and therapeutic, the overall 5-year survival
rate in many countries is generally less than 15% [3]. In
order to improve the survival rate, intensive efforts have
been made to find new anticancer agents, and many
attentions have been drawn to herbal medicines owing to
their wide range of biological activities, low toxicity and
side effects [4-6].
Osthole, 7-methoxy-8-(3-methyl-2-butenyl)coumarin
(Figure 1), is an active constituent of Cnidium monnieri
(L.) Cusson, has been extracted from many medicinal
plants such as Cnidium monnieri and other plants. Ost-
hole has long been used in traditional Chinese medicine
for the treatment of eczema, cutaneous pruritus, tricho-
monas vaginalis infection, and sexual dysfunction.
Recent studies have revealed that Osthole may have
antiproliferative [7], vasorelaxant [8], anti-inflammatory
[9], antimicrobacterial [10], antiallergic [11], and pre-
venting prophylactic effects in hepatitis [12]. Further-
more, the anticancer effect of Osthole has been reported
in few papers [13-17]. These studies have revealed that
Osthole inhibited the growth, invasion and metastasis of
cancer cells. However, the effects of Osthole on human
lung cancer cells remain unclear.
The PI3K/Akt signaling pathway is a critical transduc-
tion pathway which plays an important role in regulating
cell proliferation, cell cycle and apoptosis [18]. Various
types of cancer, including lung cancer, were reported to
aberrantly activate this pathway [19]. Recent studies have
shown that some anticancer-drugs could induce G2/M
arrest accompanying the down-regulation of Akt [20,21].
And the PI3K/Akt pathway participates in the regulation
of Bcl-2 family proteins, which are key regulators of the
apoptotic pathway [22]. In the present study, we observed
that Osthole induces G2/M arrest and apoptosis in lung
cancer A549 cells. Osthole-induced G2/M arrest and
apoptosis were associated with inhibition of the Cyclin
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Methods
Reagents
RPMI-1640, trypsin, penicillin and streptomycin were
purchased from Biological Industries (Kibutz Beit Hae-
mek, Israel). Fetal bovine serum (FBS) was purchased
from Solarbio Science&Technology (Beijing, China).
3-(4, 5-dimethyl thiazol-2yl)-2, 5-diphenyltetrazolium
bromide (MTT), dimethyl sulfoxide (DMSO), Propidium
iodide (PI), and Hoechst 33342 were purchased from
Sigma-Aldrich (St. Louis, USA). Annexin V-FITC and PI
double staining kit were purchased from Key Gene
(Nanjing, China). Osthole was purchased from the
National Institute for the control of Pharmaceutical and
biological products (Beijing, China), a 50 mM stock
solution of Osthole was dissolved in DMSO and stored
at -20°C. Antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). All other reagents were
procured locally.
Cell line and culture conditions
The human lung cancer cell line A549 was obtained
from the China Center for Type Culture Collection
(Wuhan, China) and maintained in RPMI-1640 supple-
mented with 10% FBS, 100 U/ml penicillin, and 100 μg/
ml streptomycin at 37°C in a humidified atmosphere of
5% CO2.
MTT Assay
Cell proliferation was measured using the MTT assay.
A549 cells were plated at a density of 1 × 10
4cells per
well in 96-well plates overnight and then treated with
different concentrations of Osthole (0, 25, 50, 100, 150,
and 200 μM). After 24, 48 and 72 h treatment, 20 μlo f
MTT solution (2 mg/ml in PBS) were added to each
well and the cells were cultured for another 4 h at 37°C.
Then the medium was totally removed and 150 μl
DMSO was added to solubilize MTT formazan crystals.
Finally, the plates were shaken and the optical density
was determined at 570 nm (OD570) using a ELISA plate
reader (Model 550, Bio-Rad, USA). At least three inde-
pendent experiments were performed.
Cell cycle analysis
Cell cycle was evaluated using DNA flow cytometry ana-
lysis. A549 cells were plated at a density of 1 × 10
6cells
per well in 6-well plates overnight and then treated with
different concentrations of Osthole (0, 50, 100, 150 μM).
After 48 h treatment, the cells were harvested and
washed twice with PBS, then centrifuged at 1200 ×g for
5 min, fixed in 70% ethanol at 4°C. Before flow cytome-
try analysis, the cells were washed again with PBS, trea-
ted with RNase(50 μg/ml), and stained with PI(100 μg/
ml) in the dark for 30 min. The samples were analyzed
by FACScan flow cytometer (Becton Dickinson, San
Jose, CA).
Annexin V/PI flow cytometry analysis
Apoptotic rates were determined by flow cytometry ana-
lysis using an Annexin V-FITC Apoptosis Kit. A549
cells were plated at a density of 1 × 10
6 cells per well in
6-well plates overnight and then treated with different
concentrations of Osthole (0, 50, 100, 150 μM) for 48 h.
Staining was performed according to the manufacturer’s
instructions, and flow cytometry was conducted on a
FACScan flow cytometer (Becton Dickinson, San Jose,
CA). The percentage of the early apoptosis was calcu-
lated by annexin V-positivity and PI-negativity, while
the percentage of the late apoptosis was calculated by
annexin V-positivity and PI-positivity.
Fluorescent microscopy
A549 cells were treated with different concentrations of
Osthole (0, 50, 100, and 150 μM) for 48 h. Cells were
washed twice with PBS and fixed with cold methanol
and acetic acid (3/1, v/v) before being stained with
Hoechst 33342(1 mg/ml) for 30 min at 37°C. Stained
cells were observed with a fluorescence microscope
(×400, Nikon, Japan).
Western blotting analysis
The expression of cellular proteins was evaluated by
Western blotting. After treatment for 48 h, the cells
were washed twice with ice-cold PBS. The total proteins
were solubilized and extracted with lysis buffer(20 mM
Figure 1 The structure of Osthole.
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EDTA, 0.5% NP40, 0.5 mM DTT, 1% protease inhibitor
cocktail). Protein concentration was determined by
bicinchoninic acid (BCA) protein assay. Equal amounts
of protein (50 μg) from each sample were subjected to
seperate on a SDS-PAGE. After electrophoresis, proteins
were electroblotted to polyvinylidene difluoride mem-
branes. The membranes were blocked at room tempera-
ture and then incubated at 4°C overnight with the first
antibodies of Cyclin B1, p-Cdc2, Bcl-2, Bax, t-Akt and
p-Akt seperately. After being washed three times with
T B S T ( 2 0m MT r i s - C l ,p H7 . 5 ,1 5 0m MN a C l ,1g / L
Tween20), membranes were incubated with secondary
antibodies. After incubation, the membranes were
washed three times with TBST, and visualization was
made using an ECL kit.
Statistical analysis
The data are expressed as mean ± SD. Statistical corre-
lation of data was checked for significance by ANOVA
and Student’s t test. Differences with P < 0.05 were con-
sidered significant. These analyses were performed using
SPSS 11.0 software.
Results
Osthole inhibited A549 cell proliferation
To investigate the growth inhibition effects of Osthole,
the cells were treated with different concentrations of
Osthole for 24, 48 and 72 h, and the rate of inhibition
was determined by MTT assay. We observed that
growth of A549 cells was suppressed in a dose- and
time-dependent manner(Figure 2).
Osthole induces G 2/M arrest
To determine whether Osthole inhibits the cell cycle
progression of A549 cells, the cells were treated with
different concentrations of Osthole (0, 50, 100, and
150 μM) for 48 h and the cell cycle distribution was
analyzed by flow cytometry. As shown in Figure 3, the
percentage of cells in G2/M phase with Osthole treat-
ment were 4.9%, 8.8%, 14.1% and 19.5% after 48 h,
respectively.
Osthole induces the apoptosis of A549 cells
A549 cells were treated with different concentrations of
Osthole (0, 50, 100, and 150 μM) for 48 h and were
analyzed by flow cytometry. As showed in Figure 4A, B,
the numbers of early and late apoptotic cells were signif-
icantly increased compared to control group. The pro-
portion of early and late apoptotic cells in the 150 μM
treatment group was about six times higher than in the
drug-free group. The proportion of apoptotic cells in
treated cells were increased in a dose-dependent
manner.
After incubation with different concentrations of Ost-
hole (0, 50, 100, and 150 μM) for 48 h, the cells were
examined by fluorescent microscopy analysis. As shown
in Figure 4C, condensation of chromatin, nuclear
Figure 2 The proliferative inhibition effects of Osthole on
human lung cancer A549 cells. *p < 0.001 versus control group.
Figure 3 Cell cycle distribution analysis by DNA flow
cytometry. (A) A549 cells were treated with (0, 50, 100 and 150
μM) Osthole for 48 h. Then the cells were harvested and treated
with RNase, stained with PI. The cell cycle distribution was analyzed
by flow cytometry. (B) The percentage of cells in G2/M phase in
histograms. *p < 0.01, **p < 0.001 versus control group.
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in treated cells. The results showed that when exposed
to Osthole, A549 cells underwent the typical morpholo-
gic changes of apoptosis in a dose-dependent manner.
Osthole decreases Cyclin B1 and p-Cdc2 expressions
To investigate the mechanism underlying cell cycle
arrest induced by Osthole, we tested the effect of this
compound on p-Cdc2, Cyclin B1 levels. As shown in
Figure 5, Western blotting analysis revealed that Osthole
decreased the protein levels of Cyclin B1 and p-Cdc2 via
a dose-dependent manner.
Effect of Osthole on expressions of Bcl-2 family proteins
To investigate the mechanism underlying apoptosis
induced by Osthole, we tested the effect of this
Figure 4 Apoptosis analysis by flow cytometry and fluorescent microscopy. (A) Apoptotic rates analysis by Annexin V/PI staining. A549
cells were treated with (0, 50, 100 and 150 μM) Osthole for 48 h. Then the cells were harvested and were stained with Annexin V/PI and flow
cytometric analysis was performed to analyze apoptosis rates. (B) Summaries of the apoptosis rates in histograms. *p < 0.05, **p < 0.01, ***p <
0.001 versus control group. (C) Cell apoptosis observed by Hoechst 33342 staining. A549 cells treated with (0, 50, 100 and 150 μM) Osthole for
48 h. Apoptotic cells exhibited chromatin condensations, nuclear fragmentations, and apoptotic bodies.
Figure 5 Effect of Osthole on the expressions of Cyclin B1 and
p-Cdc2 by Western blotting analysis. A549 cells were treated
with (0, 50, 100 and 150 μM) Osthole for 48 h. Proteins were
extracted, then Cyclin B1, p-Cdc2 and b-actin expressions were
analyzed by Western blotting.
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Western blotting analysis revealed that Osthole treat-
ment leads to decrease in Bcl-2 levels and increase in
Bax levels as compared to control cells. These results
indicated that Osthole up-regulation of the Bax/Bcl-2
ratio in a dose-dependent manner.
Effects of Osthole on PI3K/Akt pathway
In order to better understand the molecular basis of
Osthole induced G2/M arrest and apoptosis, we investi-
gated the expression of p-Akt and t-Akt after treatment
with Osthole(0, 50, 100, and 150 μM) for 48 h. As
shown in Figure 7, the levels of p-Akt are dose-depen-
dently decreased in response to Osthole, while the total
Akt protein levels remained constant during Osthole
treatment.
Discussion
Osthole, an active constituent of Cnidium monnieri (L.)
Cusson, extracted from many medicinal plants and herbs
such as Cnidium monnieri, Angelica pubescens and some
species of Leguminosae and Compositae.O s t h o l eh a s
been shown to have comprehensive and wider applica-
tions as anti-hepatitis, anti-oxidation, anti-inflammatory,
anti-microbacterial, and antiallergic effects [7-12].
Furthermore, the anticancer effect of Osthole has been
reported in a few papers. Both in vitro and in vivo studies
showed that Osthole possessed an anticancer effect by
inhibiting human cancer cells growth and inducing apop-
tosis [13-17]. It is reported recently that Osthole is able
to inhibit the migration and invasion of breast cancer
cells [15]. Osthole may be a good compound for develop-
ing anticancer drugs.
The induction of cell cycle arrest and apoptosis are
common mechanisms proposed for the cytotoxic effects
of anticancer-drug extracted from herbal medicine [23].
Cell cycle arrest can trigger proliferation inhibition and
apoptosis in cancer cells [24,25]. During cell cycle, the
G2/M checkpoint is a potential target for cancer ther-
apy. It prevents DNA-damaged cells from entering
mitosis and allows for the repair of DNA that was
damaged in late S or G 2 phases prior to mitosis [26].
The G2/M checkpoint is controlled by Cdc2 and Cyclin
B1 [27], and some anticancer-drugs could induce G2/M
arrest through down-regulating the expressions of
Cyclin B1 and Cdc2 [28]. The results in our study
showed that treating A549 cells with Osthole resulted in
decreased expression of Cdc2 and Cyclin B1, suggesting
that decreasing of Cdc2 and Cyclin B1 expression might
be the molecular mechanism through which Osthole
induced G2/M arrest.
Apoptosis, an important regulator in developmental
processes, maintenance of homeostasis and elimination
of the damaged cells, is the outcome of a complex inter-
action between pro- and anti-apoptotic molecules. Pro-
teins of the Bcl-2 family are key regulators of the
apoptotic pathway [29,30]. Bcl-2 family can be divided
into two subfamilies: one is anti-apoptotic protein such
as Bcl-2, the other is pro-apoptotic protein such as Bax.
Accumulated data have shown that many anticancer
agents induced apoptosis by targeting the proteins of
Bcl-2 family and the ratio of Bax/Bcl-2 played a critical
role in determining whether cells will undergo apoptosis
[31,32]. In our study, by examining the effect of Osthole
on Bax and Bcl-2, we found that Osthole increased pro-
apoptotic Bax expression and decreased anti-apoptotic
Bcl-2 expression, leading to up-regulation of the ratio of
Bax/Bcl-2. This might be one of the molecular mechan-
isms through which Osthole induces apoptosis.
The PI3K/Akt is one of the most important signaling
pathways in regulating cell growth, proliferation and
apoptosis, and Akt is a major downstream target of
PI3K [18]. The PI3K/Akt signaling pathway regulates
the development and progression of various cancers by
elevating the activity of the anti-apoptotic action of Akt,
and the phosphorylation of Akt is routinely used as
readout for the Akt activation [33]. In our study, we
evaluated the effect of Osthole on the PI3K/Akt
Figure 6 Effect of Osthole on Bcl-2 family proteins by Western
blotting analysis. A549 cells were treated with (0, 50, 100 and
150 μM) Osthole for 48 h. Proteins were extracted, then Bax, Bcl-2
and b-actin expressions were analyzed by Western blotting.
Figure 7 Effect of Osthole on the PI3K/Akt signaling pathways
by Western blotting analysis. A549 cells were treated with (0, 50,
100 and 150 μM) Osthole for 48 h. Proteins were extracted, then
p-Akt, t-Akt and b-actin expressions were analyzed by Western
blotting.
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total Akt and phospho-Akt protein. We found that
treatment of A549 cells with Osthole reduced the pro-
tein expression of p-Akt in a dose-dependent manner,
while the total Akt protein levels remained constant
during Osthole treatment. Recently studies have shown
that some anticancer-drugs could induce G2/M arrest
and apoptosis accompanying down-regulation of Akt
[20-22]. Meanwhile, we also found that Osthole treat-
ment down-regulated Cdc2/Cyclin B1, Bcl-2 protein and
up-regulated Bax in our study. In summary, these results
indicated that Osthole induced G2/M arrest and apopto-
sis possibly by down-regulating Akt signaling in human
lung cancer A549 cells.
Conclusions
Our studies demonstrated that Osthole inhibited the
growth of human lung cancer A549 cells by inducing
G2/M arrest and apoptosis. This might be the important
mechanisms of Osthole suppressed the growth of the
lung cancer cells. Our findings suggest that Osthole may
have a therapeutic application in the treatment of
human lung cancer.
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